Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Krystal Biotech (KRYS) is trading at $334.85, up 3.90% on the day. Its market value of $9.91B makes it the 1468th largest of the 2132 companies we follow.
The 52-week range is $179.19 to $382.54. Today's price is about 77% of the way from the low to the high. Holders are ahead 85.4% over twelve months, but down 9.2% across the last three months.
Price is below the 50-day average ($342.42) but above the 200-day ($301.86); RSI is 47, and the last 30 sessions moved at roughly 32% annualized volatility.
Buyers are paying 42.0 times trailing earnings.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 2132 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
KRYS is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.3% | Bearish |
| Price vs 50-day average | -2.2% | Bearish |
| Price vs 200-day average | +10.9% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 46.6 | Bearish |
| MACD (12,26,9) | -4.29 | Bearish |
| Bollinger band position | 36% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 2,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$334.85 is the latest print for KRYS, a move of +3.90% against yesterday's close of $322.28. Today's low and high so far: $321.37 and $339.69.
Equity value comes to $9.91B at the current price. By that measure it is number 1468 of the 2132 names in our coverage.
Buyers pay 42.0 times the last twelve months of profit (EPS $6.84).
The year's floor is $179.19 and the ceiling $382.54. Shares are 12.5% away from that ceiling.
Our data shows no dividend paid by Krystal Biotech over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on KRYS.